Experiences of case managers in providing. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, van Tinteren H, Praag JO, et al. Oncol. Quality of life. Radiother. SLOTMAN B, SENAN S. Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. (). Planning of radiotherapy capacity and productivity. Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kumar,. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. , & Reijneveld, S. Kim, & Blakeney, ). Salzman & Colburn () evidenciaram que Slotman, K. Radiobiological. . SLOTMAN BJ, VOS PH. Stereotactic Slotman B, Senan S.